open access

Vol 12, No 1 (2017)
Case Reports
Published online: 2017-03-03
Get Citation

Primum non nocere. Difficulties related to anticoagulation therapy of elderly patients

Michał Narożny, Grzegorz Skonieczny
DOI: 10.5603/FC.2017.0011
·
Folia Cardiologica 2017;12(1):91-95.

open access

Vol 12, No 1 (2017)
Case Reports
Published online: 2017-03-03

Abstract

The first step of anticoagulant therapy is to make a therapeutic decision based on absolute risk of embolism and bleedings and on patient’s benefit-risk ratio. Clinical case has been analyzed of the elderly patient with numerous comorbidities and high risk of bleeding who requires anticoagulant therapy. The objective of this study was to emphasize the variability of bleeding risk during long-term treatment. Based on clinical trials and current guidelines, novel oral anticoagulants can be considered superior to classical therapy with vitamin K antagonists.

Abstract

The first step of anticoagulant therapy is to make a therapeutic decision based on absolute risk of embolism and bleedings and on patient’s benefit-risk ratio. Clinical case has been analyzed of the elderly patient with numerous comorbidities and high risk of bleeding who requires anticoagulant therapy. The objective of this study was to emphasize the variability of bleeding risk during long-term treatment. Based on clinical trials and current guidelines, novel oral anticoagulants can be considered superior to classical therapy with vitamin K antagonists.

Get Citation

Keywords

anticoagulation therapy, anticoagulant, rivaroxaban, dabigatran, overdose, side effect

About this article
Title

Primum non nocere. Difficulties related to anticoagulation therapy of elderly patients

Journal

Folia Cardiologica

Issue

Vol 12, No 1 (2017)

Pages

91-95

Published online

2017-03-03

DOI

10.5603/FC.2017.0011

Bibliographic record

Folia Cardiologica 2017;12(1):91-95.

Keywords

anticoagulation therapy
anticoagulant
rivaroxaban
dabigatran
overdose
side effect

Authors

Michał Narożny
Grzegorz Skonieczny

References (5)
  1. Wallentin L, Yusuf S, Ezekowitz MD, et al. RE-LY investigators. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet. 2010; 376(9745): 975–983.
  2. Patel MR, Mahaffey KW, Garg J, et al. ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011; 365(10): 883–891.
  3. Camm AJ, Lip GYH, De CR, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012; 33(21): 2719–2747.
  4. Pisters R, Lane D, Nieuwlaat R, et al. A novel userfriendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial Ffbrillation. Chest. 2010; 138(5): 1093–1100.
  5. Mant J, Hobbs FD, Fletcher K, et al. BAFTA investigators, Midland Research Practices Network (MidReC). Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet. 2007; 370(9586): 493–503.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

 

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl